SMMT 8-K: Fda rejection

The FDA

Filed with the SEC on · accession 0001599298-26-000092

SMMT filed a 8-K (current report) with the SEC on Nov 16, 2026. The FDA issued a Complete Response Letter to Summit Therapeutics regarding its BLA for ivonescimab in combination with platinum-containing chemotherapy for previously treated EGFR-mutant non-small cell lung cancer.

Summary of the filing

The FDA issued a Complete Response Letter to Summit Therapeutics regarding its BLA for ivonescimab in combination with platinum-containing chemotherapy for previously treated EGFR-mutant non-small cell lung cancer. The FDA determined that substantial evidence of effectiveness was not established absent a statistically significant overall survival benefit, and the BLA cannot be approved in its present form.

Key details

Registrant / bla sponsorSummit Therapeutics Inc.
Regulatory agency that issued the complete response letterU.S. Food and Drug Administration
Chief operating officer, chief financial officer and directorManmeet S. Soni

✦ Ask GOAX AI about this filing — what it means for SMMT, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for SMMT?

Click here

Frequently asked questions

What did SMMT file with the SEC on Nov 16, 2026?

SMMT filed a 8-K (Fda rejection). The FDA issued a Complete Response Letter to Summit Therapeutics regarding its BLA for ivonescimab in combination with platinum-containing chemotherapy for previously treated EGFR-mutant non-small cell lung cancer. The FDA determined that substantial evidence of effectiveness was not established absent a statistically significant overall survival benefit, and the BLA cannot be approved in its present form.

What does a fda rejection mean for SMMT stock?

For a small biotech one drug can be most of the company’s value. Approval opens sales; a rejection (complete response letter) can delay it by years.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other SMMT SEC filings

Get alerts when SMMT files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days